RxDoctor Payments Data

Timothy Simpson, MD

Interventional Cardiology · Vancouver, WANPI 1396187696

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (44.7%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Abbott at 35.5% of the total. Reporting peaked in 2021 at $6,117 and has fallen 87.3% since, to $775 in 2025.

$12,679in general payments, 2019–2025

Across 169 payments — averaging $75.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Biotronik Inc.$4K
  • Abiomed$1K
  • Edwards Lifesciences$1K
  • Boston Scientific$597
  • Medtronic$524
  • plus $850 from 11 others

What the payments were for

  • Speaking & faculty fees$1,1329%
  • Grants$3493%
  • Travel & lodging$4,67637%
  • Food & beverage$5,66245%
  • Education$8607%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,679 in reported general payments places this provider in the 70th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$65,204
Medicare patients
352
Services billed
684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$67,455
JardianceEmpagliflozin56$51,267
EntrestoSacubitril/Valsartan16$15,257
FarxigaDapagliflozin Propanediol12$12,713
Repatha SureclickEvolocumab14$8,539
Metoprolol Succinate164$1,759
Rosuvastatin Calcium69$1,076
Atorvastatin Calcium97$998
Losartan Potassium71$586
Torsemide12$584
ClopidogrelClopidogrel Bisulfate36$389
Furosemide85$387
Ezetimibe33$355
Potassium Chloride24$336
Lisinopril33$242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$67,45570 claims
AstraZenecaFarxiga$23$12,71312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 125 interventional cardiology providers in Washington.

Other interventional cardiology in Vancouver

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →